August 19, 2014 8:18am
BARDA executes Contract Option for continued development of Thermal Burn Injury Counter Measure
Option valued at $12.1 M plus $8.3 M for FDA approved IDE Trial
Members only. Please login.
August 19, 2014 8:18am
BARDA executes Contract Option for continued development of Thermal Burn Injury Counter Measure
Option valued at $12.1 M plus $8.3 M for FDA approved IDE Trial
Members only. Please login.
35 companies, 1 interpreter!
Insight, foresight and recommendation
2 hours 30 min ago
RegMed Investors (RMi) Closing Bell: starting with sector slippage to a neutral mid-day ending with a negative close
6 hours 48 min ago
RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results
8 hours 37 min ago
RegMed Investors (RMi) Research Note: Q1/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes
11 hours 27 min ago
RegMed Investors’ (RMi) pre-open: quiet weeks of economic data and sector earnings will flip the sentiment switch
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.